Bisphenol A (BPA) was first developed in the 1930s and is presently used in the manufacture of many polycarbonate plastic containers (including baby bottles and reusable water bottles), dental sealants, metallic food cans, paper, and cardboard items ([@r3]; [@r13]; [@r16]). Because this chemical was assumed to be relatively harmless, demand for these products has increased, and so has the manufacture of BPA, which is now produced in amounts exceeding 8 billion pounds/year, with little signs of diminution of output ([@r1]). BPA is stable in sediment and detectable in almost all bodies of water ([@r10]). Thus, exposure of wildlife and humans to BPA is inevitable, likely to continue, and even to increase ([@r34]). Human and animal contact with BPA can occur through various sources, and whether diet is the primary source of exposure remains unresolved ([@r26]). Regardless, \> 90% of people in the United States have measurable levels of BPA ([@r4]), and there is no reason to suppose that the reach of BPA is not global ([@r31]).

The overarching question concerns the total amount of BPA that most humans are subjected to on a daily basis. An attendant question is whether these exposures lead to adverse outcomes. Although a handful of studies have tried to address this question by measuring serum and urinary concentrations of BPA in human populations, great variability exists in the exact estimates \[Food and Drug Administration (FDA) 2008; Vandenberg et al. 2007; vom Saal et al. 2007\]. For instance, the FDA estimated that the daily BPA exposure for adults is 0.16 μg/kg/day (FDA 2008). However, based on the available data at the time, a conference sponsored by the National Institute of Environmental Health Sciences in 2007 predicted that internal exposure (plasma or serum concentrations) in humans is \> 35 mg/day (\~ 500 μg/kg/day)  ([@r33]; [@r36]). This prediction has been updated ([@r31]) to reflect mounting evidence suggesting that human exposure to BPA can occur through routes other than diet and water consumption ([@r14]; [@r32]).

A major hurdle in estimating human exposure to BPA is accounting for all of the potential routes of exposure, even though contaminated food and beverages are still considered the dominant source for this chemical ([@r13]; [@r34]; [@r38]). For example, BPA exposure might also occur through less-explored routes, including dermal contact with thermal (carbonless) receipts, inhalation of household dusts, and cigarette smoke ([@r3]; [@r13]; [@r16]). Only one published study to date has examined the elimination of BPA from blood after a single oral administration to volunteer human subjects, and this study failed to detect active BPA in the serum of these individuals ([@r35]), most probably because concentrations fell below the detection limit of the relatively insensitive assay employed ([@r28]; [@r34]). Rather than recognize the potential limitation of that study, some investigators have used the data to conclude that unconjugated BPA is so rapidly metabolized and/or cleared that it is relatively harmless to humans ([@r6]; [@r38]).

Rodent models have been criticized as inappropriate to calculate human BPA exposures based on the prediction of species differences in metabolism of BPA ([@r6]), although this conclusion was disputed by an expert panel of the Food and Agriculture Organization of the United Nations and the World Health Organization (2010). Although both adult rodents and primates use glucuronidation of BPA through uridine 5´-diphospho-glucuronosyltransferases as part of their phase II metabolism system, the primary mechanism through which BPA is cleared from blood differs, with urinary excretion being the primary route in primates versus the biliary--fecal route in rodents ([@r17]; [@r25]). BPA might also be metabolized by sulfonation, but this form accounts for only a very minor component across various adult animal species ([@r2]; [@r20]; [@r24]). Enterohepatic recirculation of BPA is less prominent in primates than in rodents, but even in rats and mice, enterohepatic recirculation is not a major factor ([@r7]; [@r28]). A recent study that performed a side-by-side analysis of the serum concentrations of BPA in CD1 mice and rhesus monkeys (*Macaca mulatta*) that had, in each case, received an oral bolus of the chemical concluded that the clearance of unconjugated BPA over 24 hr was comparable in the two species ([@r28]) and similar to what had been observed in a second macaque species, *Macaca fascicularis* ([@r30]). Thus, by these criteria, mice appear to be an acceptable animal model to predict the pharmacokinetic of BPA in nonhuman primates and potentially, by extrapolation, in humans ([@r14]; [@r28]).

Both in the single human study by [@r35] and in the various trials performed on nonhuman primates and rodents, serum concentrations of conjugated and unconjugated BPA have invariably been measured after administering a single dose of the chemical as either an oral bolus or via subcutaneous injection ([@r7], [@r8]; [@r28]; [@r34]), whereas continuous exposure through the diet seems more likely to mimic exposures outside the laboratory. Moreover, dietary BPA exposure would be a more appropriate and convenient route than bolus exposure for studies of the developmental effects of *in utero* BPA exposure on offspring and adults. Although pregnant mice fed a diet containing BPA have given birth to offspring with epigenetic ([@r9]) and behavioral abnormalities ([@r5]), neither study measured serum concentrations of BPA during pregnancy. Finally, it remains controversial whether the quantities of BPA supplied to mice in these studies reflect exposure levels that might be expected to occur outside of the laboratory. In the present study, we measured serum concentrations of BPA in mice exposed through natural feeding behavior to more precisely characterize circulating concentrations resulting from dietary exposure and compared concentrations with those in mice exposed through single oral bolus exposure, as in previous studies ([@r7], [@r8]; [@r28]). Instead of using BPA, we employed the isotopically tagged form, \[dimethyl-d~6~\]-BPA (BPA-*d*~6~; C/D/N Isotopes Inc., Quebec, Canada), to ensure that only the BPA provided experimentally was assayed.

Materials and Methods
=====================

*Animals.* All animal experiments were approved by the University of Missouri Animal Care and Use Committee and performed in accordance with National Institutes of Health animal care and use guidelines (Institute of Laboratory Animal Resources 1996). All animals were treated humanely and with regard for alleviation of suffering. Adult (10--12 weeks of age) C57Bl/6J female mice were purchased from Jackson Labs (Bar Harbor, ME, USA). On arrival, animals were placed on AIN93G diet (Harlan Teklad, Madison, WI, USA) \[see Supplemental Material, [Table 1](#t1){ref-type="table"} (<http://dx.doi.org/10.1289/ehp.1003385>)\], and their food consumption and body weights (BWs) (mean ± SE, 19.1 ± 0.5 g) were measured daily. Mice were maintained on a 12-hr dark:12-hr light cycle with lights out at 1900 hours. To minimize background BPA exposure, mice were housed in polypropylene cages and provided glass water bottles. Their water was stringently purified by a reverse osmosis and carbon filtration system and did not contain detectable BPA.

###### 

Pharmacokinetics parameters of BPA‑*d*~6~ obtained after NCA of unconjugated and total BPA‑*d*~6~ serum concentrations in mice over a 24-hr period after exposure via oral bolus or diet.

  Oral bolus (20 mg/kg BW)                                  Diet (13 mg/kg BW)*a*                                                             
  --------------------------------------------------------- ----------------------- -------------- -- ------------------ -- -------------- -- ------------------
  *C*~max~ (ng/mL)                                                                  21.0 ± 3.9        1636.5 ± 642.6        18.8 ± 4.4        802.2 ± 126.6
  AUC~0--24hr~ (ng.hr/mL)                                                           201.0 ± 20.6      21979.3 ± 3813.5      147.8 ± 26.7      11547.3 ± 1219.5
  Average 24-hr concentration (ng/mL)                                               8.3               915.8                 6.1               481.1
  AUC~0--24hr~ total/unconjugated BPA‑*d*~6~                                        109               79                                      
  **a**Estimated ingested dose based on food consumption.                                                                                     

*BPA-*d*~6~ treatments.* Based on the widely accepted studies demonstrating that BPA disposition is linear over a wide range of doses, including in humans ([@r7]; [@r28]; [@r29]; [@r33]), our experiments were confined to a single test dose that would provide detectable and accurate measurements for mice exposed to BPA-*d*~6~ through diet or oral bolus exposure. At 1900 hours (the beginning of the dark cycle), one group of nonfasted mice that had not yet initiated their nocturnal feeding received a single oral bolus of 20 mg/kg BW BPA-*d*~6~ in an exceedingly small volume (40 μL) of tocopherol-stripped corn oil (MP Biomedicals, LLC, Solon, OH, USA). These mice continued to receive AIN93G diet after exposure. This oral bolus dose was chosen to approximate the amount of BPA-*d*~6~ that mice on a diet containing 100 mg BPA-*d*~6~/kg feed weight \[see Supplemental Material, Table 2 (<http://dx.doi.org/10.1289/ehp.1003385>)\] had been predicted to consume in a 24-hr period based on preliminary data and data from another published study using the same strain of mice ([@r5]).

For the BPA-*d*~6~ diet--exposed group, the food placed at the beginning and remaining at the end of each time point was weighed to calculate the amount consumed. Each mouse was weighed immediately before it was killed for blood collection. Two to four mice for each time point and group were caged together to reduce space. To account for the varying numbers of mice in the cage, each cage was considered a unit, and the total consumption for each cage was divided by the average weight of the mice in this cage.

Serum samples from mice that had not been administered BPA-*d*~6~ were collected from females (*n* = 12) maintained on AIN93G diet beginning at 1900 hours, which is when mice normally begin nocturnal feeding at the beginning of the dark phase of the dark:light cycle ([@r19]). Representative mice from the diet and oral bolus groups (*n* = 8 for each time point) were culled and cardiac blood was collected 1 hr, 4 hr, 6 hr, 11 hr, 24 hr, and 7 days (168 hr) after initiating exposure to BPA-*d*~6~ at 1900 hours. For additional information on BPA-*d*~6~ treatments, see Supplemental Material, p. 3 (<http://dx.doi.org/10.1289/ehp.1003385>).

*Analysis of unconjugated and conjugated BPA-*d*~6~ in mouse serum samples.* BPA-*d*~6~ serum concentrations were measured as described previously ([@r23]) but with some modifications. The mouse serum samples were divided into two aliquots (each of 150--200 μL) for the analysis of free and total BPA-*d*~6~, respectively. A reference standard \[5 ng deuterated 16-BPA (BPA-*d*~16~)\] was included as a quality control to validate the method, as the inclusion of BPA-*d*~16~ into the test serum samples served as an internal control to estimate recovery through the analytical steps. Analyte separation and detection were carried out by using an Agilent 1100 series HPLC interfaced with an Applied Biosystems API 2000 electrospray MS/mS mass spectrometer (Applied Biosystems, Foster City, CA, USA). Additional information is provided in Supplemental Material, pp. 3--5 (<http://dx.doi.org/10.1289/ehp.1003385>).

*Statistical analysis.* We used analysis of variance and SAS software (version 9.2; SAS Institute Inc., Cary, NC, USA) to analyze differences in serum concentrations of unconjugated and total BPA-*d*~6~ within diet and oral bolus groups. However, because there were heterogeneous variances, tests for significance were performed after log~10~ transformation. The linear statistical model was a two by seven factorial (two treatments, seven time points). If main effects were statistically significant at *p* \< 0.05, mean differences were determined using Fisher's least significant difference. All data are presented as mean ± SE.

*Pharmacokinetic analysis.* Unconjugated and total serum concentration--time profiles after oral and diet BPA-*d*~6~ exposure were analyzed with a noncompartmental analysis (NCA) using WinNonlin (WinNonlin® Professional, version 5.3; Pharsight Corporation, Cary, NC, USA). We calculated area under the curve (AUC) up to the last quantifiable serum concentration \[i.e., AUC~(0--24hr)~\], using the linear trapezoidal rule. For additional information on NCA analysis, see Supplemental Material, p. 5 (<http://dx.doi.org/10.1289/ehp.1003385>). The sparse data option of WinNonlin was used, allowing computation of the different SEs associated with estimated parameters (see Supplemental Material, Tables 3--5).

We analyzed unconjugated BPA-*d*~6~ serum concentrations after oral exposure with a compartmental analysis using a monocompartmental model without lag time. Pooled data were fitted using the following equation (the so-called Bateman equation):
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where *C*(*t*) is the pooled BPA-*d*~6~ serum concentration at time *t*, *F* is the unknown bioavailability of BPA-*d*~6~, dose is the BPA-*d*~6~ dose, *V* is the volume of distribution (milliliters per kilogram), *K*~01~ (per hour) is the first-order rate constant of absorption and *K*~10~ (per hour) is the first-order rate constant of elimination. *V/F*, *K*~10~, and *K*~01~ were estimated. Iterative reweighting was used during minimization process, that is, the data were weighted by the inverse of the observed value (1/*Y*~obs~) \[see Supplemental Material, [Figure 1](#f1){ref-type="fig"} (<http://dx.doi.org/10.1289/ehp.1003385>)\]. The goodness of fit of the model was assessed by using least-squares criteria and visual inspection of residuals. Weighted residuals are presented in Supplemental Material, [Figure 2](#f2){ref-type="fig"}. For additional information on compartmental analysis, see Supplemental Material, p. 6.

![Cumulative diet exposure to BPA‑*d*~6~ versus time and night/day cycle estimated by amount of food consumed and by deconvolution. Deconvolution analysis was performed by using the oral bolus administration as a reference to evaluate the *in vivo* BPA‑*d*~6~ input rate (BW) over 11 hr (i.e, during the night). Time points with different superscripts are significantly different from each other based on log~10~ scale analysis (*p* \< 0.01).](ehp.1003385.g001){#f1}

![Arithmetic plot of the mean (± SE) serum concentrations of unconjugated BPA‑*d*~6~ (*A*) (and the total BPA‑*d*~6~ serum concentrations (*B*) versus time and versus night/day cycle after a single oral bolus of BPA‑*d*~6~ at 20 mg/kg BW or after exposure to BPA‑*d*~6~ at 100 mg/kg feed weight (13 mg/kg BW in the first 24 hr; see Figure 1) in mice. For the oral bolus, *C*~max~ for unconjugated BPA‑*d*~6~ and total BPA‑*d*~6~ occurred 1 hr after the treatment (2000 hours). In contrast, *C*~max~ was not obtained until 6 hr after treatment (0100 hours) in the diet-exposed group. Within each treatment group, values with different superscripts are significantly different (*p* \< 0.05).](ehp.1003385.g002){#f2}

The relative bioavailability between the two conditions of administration was calculated from the following equation:
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*AUC*~(0--24hr)oral\ bolus~ and *AUC*~(0--24hr)diet~  (the AUC of unconjugated serum BPA) was estimated by noncompartmental analysis, and Dose~oral\ bolus~ and Dose~diet~ were the actual nominal dose and dose ingested through the diet, respectively, with the diet dose estimated by food consumption. We also used [Equation 2](#e2){ref-type="disp-formula"} to estimate the extent of BPA-*d*~6~ absorption replacing unconjugated BPA-*d*~6~ AUCs by the corresponding total BPA-*d*~6~ AUCs.

We used deconvolution to evaluate *in vivo* drug release and delivery when data from a known drug input were available (i.e., the kinetics after the oral bolus BPA-*d*~6~ administration). The BPA-*d*~6~ input rate evaluated when BPA-*d*~6~ was administered in the diet corresponded to the *in vivo* BPA-*d*~6~ release from food followed by a BPA-*d*~6~ delivery to the general systemic circulation. In this experiment, deconvolution was used to evaluate the *in vivo* BPA-*d*~6~ input rate (milligrams per hour) into blood of mice fed during the night. Data from 0 to 11 hours (i.e., only data collected during the nocturnal period) were considered. The reference BPA input was obtained from the bolus oral administration for which the input into the digestive tract was instantaneous (drenching). The deconvolution analysis was performed using the mean of pooled unconjugated BPA-*d*~6~ serum concentrations after diet exposure over time. More details and results of these analyses are included in Supplemental Material, pp. 5--8, 11--18, and 21; Tables 3--7; and Figures 3 and 4 (<http://dx.doi.org/10.1289/ehp.1003385>).

Results
=======

*Measurement of external cumulative exposure rate to BPA-*d*~6~ in diet-exposed mice.* By knowing the weight of BPA-*d*~6~--supplemented diet provided at the outset of the experiment, the amounts remaining at each time point of serum collection, and the weight of the mice in each cage at the time of serum collection, we could calculate the cumulative exposure of BPA-*d*~6~ (milligrams per kilogram) in the diet-exposed group ([Figure 1](#f1){ref-type="fig"}). Mice were placed on the BPA-*d*~6~ supplemented diet at 1900 hours (i.e., at the end of their normal light cycle), and within the first 6 hr (i.e., by 0100 hours) the animals had eaten about 50% of the food consumed over 24 hr ([Figure 1](#f1){ref-type="fig"}). By this time point, mice had consumed 6.5 ± 0.4 mg/kg BPA-*d*~6~ (mean ± SE). After 11 hr, consumption had increased to 8.6 ± 1.3 mg/kg and at 24 hr had reached 13.0 ± 1.1 mg/kg. After 7 days of consuming the BPA-*d*~6~--supplemented diet, the total ingested dose was 78.1 ± 0.7 mg/kg rather than the 140 mg/kg expected dose.

No differences in BW were observed among the mice on the two treatment regimens, and overall body mass did not change significantly over the 7-day experimental period. In addition, none of the mice showed outward signs of ill health. These data thus suggest that BPA-*d*~6~ in the feed was well tolerated.

*Measurement of internal exposure to unconjugated BPA-*d*~6~ in serum.* For mice receiving the oral bolus (20 mg/kg BW), maximum concentration (*C*~max~) of unconjugated BPA-*d*~6~ (21.0 ± 3.9 ng/mL, mean ± SE) occurred within 1 hr (i.e., by 2000 hours) of administration of BPA-*d*~6~ ([Table 1](#t1){ref-type="table"} and [Figure 2A](#f2){ref-type="fig"}) and declined slowly thereafter, reaching barely detectable concentrations after 24 hours (i.e., at 1900 hours the day after bolus administration). In the diet-exposed group, the estimated dose was 13 mg/kg BW over the first 24 hr, and peak BPA-*d*~6~ concentrations (18.8 ± 4.4 ng/mL) were not observed until 6 hr (0100 hours) after the initiation of the BPA-*d*~6~--supplemented diet ([Table 1](#t1){ref-type="table"} and [Figure 2A](#f2){ref-type="fig"}); unconjugated serum BPA-*d*~6~ concentrations declined significantly by 11 hr. However, because *C*~max~ occurred after consuming only 6.5 mg/kg BW of BPA-*d*~6~ ([Figures 1](#f1){ref-type="fig"} and [2](#f2){ref-type="fig"}), we derived a scaled *C*~max~ value for dietary exposure consistent with the oral bolus dose of 20 mg/kg BW \[i.e., (20 mg/kg ÷ 6.5 mg/kg) × 18.8 ng/mL\] resulting in an estimated peak concentration of 57.9 ng/mL for diet exposure. Unconjugated BPA-*d*~6~ serum concentrations collected at 1900 hours from mice on BPA-*d*~6~--containing diet for 7 days were higher than unconjugated BPA-*d*~6~ serum concentrations in mice on this diet for 24 hr (13.2 ± 5.2 ng/mL versus 6.9 ± 3.3 ng/mL, *p* \< 0.05), revealing that significant buildup of biologically active BPA-*d*~6~ had occurred during the 7-day exposure period. To compare the oral bolus and diet groups at the same external dose, we scaled the dose of the diet-exposed group to 20 mg/kg BW, and the AUC~(0--24hr)~ was modestly greater (but not statistically significant) in the diet group compared with the oral bolus group (227.4 ± 41.1 and 201.0 ± 20.6 ng-hr/mL, respectively), indicating a relative bioavailability of 113% for the diet group.

Rate constants (initial and terminal rates) were estimated by using compartmental analysis to fitted unconjugated BPA-*d~6~* serum concentrations after oral bolus exposure \[see Supplemental Material, [Figure 1](#f1){ref-type="fig"} (<http://dx.doi.org/10.1289/ehp.1003385>)\]. The terminal half-life of BPA-*d*~6~ was estimated to be 6.4 ± 1.1 hr (mean ± SE, see Supplemental Material, Table 6). Deconvolution analysis for time development of the internal exposure in the diet-exposed group supported our original finding on exposure rate obtained with food consumption. When bolus administration of BPA-*d*~6~ was used as the reference, the total estimated bioavailable BPA-*d*~6~ dose between 0 and 11 hr after the beginning of diet exposure based on deconvolution analysis was 15.6 mg/kg, which is close to the 13 mg/kg BW estimated by actual weighing of ingested food ([Figure 1](#f1){ref-type="fig"}; see also Supplemental Material, Figures 3 and 4). From the deconvolution analysis, it appeared that most of BPA-*d~6~* ingestion was during the first part of the night, and 90% of the bioavailable BPA had been computed to be absorbed into the bloodstream by 5.46 hr after the beginning of the diet exposure (i.e., before 0100 hours the next day) (see Supplemental Material, Table 7).

*Measurement of internal exposure to total BPA-*d*~6~ in serum.* Total BPA is the sum of the unconjugated and conjugated BPA-*d*~6~ in the serum of exposed mice. Concentrations of the conjugated form were up to 70--100 times higher than those of unconjugated BPA ([Table 1](#t1){ref-type="table"}), which could account for the differences in blood clearance between conjugated and unconjugated forms. In the oral bolus group, peak concentrations (i.e., presumed *C*~max~) of conjugated BPA-*d*~6~ occurred by 1 hr (at 2000 hours) after treatment (1596.7 ± 1006.6 ng/mL, mean ± SE) ([Figure 2B](#f2){ref-type="fig"}). In the oral bolus group, there was a second increase, which in contrast to unconjugated BPA-*d*~6~ data was statistically significant between the 4-hr collections (2300 hours) and the measurements at 6 hr (693.2 ± 176.9 ng/mL versus 1636.5 ± 642.6 ng/mL; *p* \< 0.0.01) and at 11 hr (1200.5 ± 252.8) ([Figure 2B](#f2){ref-type="fig"}). By 24 hr, however, total BPA-*d*~6~ had declined markedly in both groups to about 5% of their peak concentrations noted at 1 hr. The *C*~max~ for the diet group (802.2 ± 126.6 ng/mL) was achieved later (at around 6 hr; 0100 hr) than in the bolus group ([Figure 2B](#f2){ref-type="fig"}), thus mirroring the data for unconjugated BPA-*d*~6~ ([Figure 2A](#f2){ref-type="fig"}).When total BPA-*d*~6~ concentrations for diet exposure were scaled to the oral bolus dose \[i.e., (20 mg/kg ÷ 6.5 mg/kg) × 802.2 ng/mL\], the estimated peak concentration for the diet-exposed group was 2468.3 ng/mL. Total BPA-*d*~6~ concentrations declined after 6 hr in the diet-exposed group ([Figure 2B](#f2){ref-type="fig"}). Concentrations of total serum BPA-*d*~6~ at 24 hr and 7 days in the diet-exposed group were not significantly different (193.9 ± 44.4 ng/mL vs. 359.6 ± 64.23 ng/mL; *p* \> 0.05).

Assuming that total BPA-*d*~6~ is formed only by a hepatic first-pass effect ([@r6]), the AUC for total BPA-*d*~6~ reflects the extent of BPA-*d*~6~ absorption, whereas the amount of unconjugated BPA-*d*~6~ that reaches systemic circulation after escaping hepatic first-pass metabolism reflects the extent of BPA-*d*~6~ bioavailability. The AUC~0--24hr~ for diet exposure and bolus administration at the same external dose were 11547.3 ± 1219.5 and 21979.3 ± 3813.5 ng-hr/mL, respectively, indicating a relative absorption of 81% for the diet group. Thus, less total BPA-*d*~6~ was absorbed after diet exposure than after oral bolus administration. Consequently, the higher bioavailability associated with diet exposure (113%) is presumably explained by postabsorption events rather than by increased BPA-*d*~6~ absorption.

Discussion
==========

Previous studies have demonstrated that exposure to BPA through diet can induce epigenetic and behavioral changes in mice ([@r5]; [@r9]), suggesting that exposure to BPA has measurable biochemical and phenotypic effects in animals. However, to our knowledge, the present study is the first to quantify serum BPA concentrations in any species after exposure through the diet. We chose an external exposure of BPA that was lower than the lowest observed adverse effect level of 50 mg/kg BW/day reported in rodents ([@r5]) but still within the detection limit of the assay that would yield accurate measurements. Because phase II enzymes are not saturable within many orders of magnitude of human exposure, it is commonly accepted that BPA concentrations in the systemic blood are linear over a wide range of doses ([@r7]; [@r28]; [@r29]; [@r33], [@r31]), thereby negating the need to measure internal concentrations after much lower doses of BPA-*d*~6~. Intake of BPA-*d*~6~ at the levels used in our study, either as a single bolus dose or through *ad libitum* feeding, allowed us to measure both unconjugated and total BPA-*d*~6~ in the serum of the exposed C57Bl/6J female mice using a combination of HPLC and tandem mass spectrometry. The inclusion of a separate, spiked, deuterated form of BPA, (BPA-*d*~16~) in the collected serum served as an internal control to estimate recovery through the analytical steps. Moreover, the BPA-*d*~6~ consumed could be distinguished from any contaminating compound and the internal control by virtue of the transitions of 233 *m/z* \> 215 *m/z* for BPA-*d*~6~ and 241 *m/z* \> 223 *m/z* for BPA-*d*~16~. Hence, the method was not only sensitive but specific and accurate for the compounds analyzed.

Although the spacing of sampling times did not permit precise pharmacokinetic profiles to be assessed, it was possible to compare the consequences of ingestion of BPA-*d*~6~ as a bolus versus *ad libitum* consumption in the food, which was the primary goal of the study. Most studies on the effects of BPA in rodents or in nonhuman primates and humans have used a single bolus administration ([@r7], [@r8]; [@r28]). We have shown that BPA-*d*~6~ is rapidly metabolized to one or more conjugated forms and that both free and conjugated forms are cleared fairly rapidly from serum after exposure through diet as well as after oral bolus administration. The terminal half-life value for disposition of the unconjugated form of BPA-*d*~6~ after bolus administration was approximately 6 hr, and thus by 24 hr this group had low circulating concentrations of the substance.

An important finding from our experiments is that the bioavailability is higher after diet administration than after bolus administration of BPA-*d*~6~, despite evidence of lower relative absorption after diet administration. This finding may be tentatively explained by a "food-effect," which has been previously described for several highly extracted drugs ([@r27]; [@r37]). Specifically, it has been hypothesized that food transiently inhibits the intrinsic ability of the liver to metabolize highly extracted substances (i.e., chemicals that are preferentially metabolized by the liver), particularly during the absorption phase ([@r27]; [@r37]). Thus, consumption of BPA-*d*~6~ in food increased its internal bioavailable concentrations, despite lower BPA-*d*~6~ absorption, relative to oral bolus exposure. When the treatments were initiated at the beginning of the dark phase (1900 hours), neither oral bolus nor diet- exposed groups had commenced their nocturnal feeding. After treatments were initiated, both groups were fed the same amount of a diet that was identical except for the addition of BPA-*d*~6~ \[see Supplemental Material, [Tables 1](#t1){ref-type="table"} and 2 (<http://dx.doi.org/10.1289/ehp.1003385>)\]. It is unlikely that the very small volume of corn oil used for oral bolus administration affected the results, particularly because maximum concentrations (*C*~max~) also occurred 1 hr postadministration in mice provided an oral bolus of BPA-*d*~6~ during the light phase (versus the dark phase) of the cycle ([@r28]). Moreover, although the scaled *C*~max~ (57.9 ng/mL) after administration of BPA-*d*~6~ in the diet was almost three times higher than the *C*~max~ after oral bolus exposure (21.0 ng/mL), the scaled AUC for diet versus oral bolus exposure was only increased by about 13%. This difference between *C*~max~ and AUC is consistent with a transient food effect increasing *C*~max~ but not AUC, which was calculated over a 24-hr period (i.e., before and after the *C*~max~ period). These findings of the effect of food on BPA absorption might account for the spurious or dramatic variations in peak plasma concentrations observed in human biomonitoring studies ([@r32]).

Our finding that diet exposure resulted in increased serum concentrations of active BPA-*d*~6~ is relevant to animals and humans, where a significant portion of the total exposure to BPA is believed to occur through diet ([@r21]). Recently, [@r29] demonstrated that in humans there is considerable inter- and intrameal variability in BPA urinary excretion, consistent with an estimated range of exposure from 3.29 to 73.29 μg. However, these findings might also be explained by a food effect, the inhibitory effect of food on first-pass hepatic metabolism. In addition, BPA exposure through food consumption is experimentally more convenient; because it is less stressful than other routes of administration, it may provide a more relevant pharmacokinetic profile by reducing stress-related confounds.

Another potential noteworthy finding is possible bioaccumulation of free BPA when BPA-*d*~6~ is provided through the diet, which has not been observed when BPA is administered as a single bolus ([@r7]; [@r28]). For example, in the 24-hr experiment, concentrations of free BPA-*d*~6~ were significantly higher in the diet-exposed group than in mice given BPA-*d*~6~ as a single bolus. In addition, concentrations of unconjugated or active BPA-*d*~6~ in the diet group were higher after 7 days of dietary exposure than at 24 hr after exposure. One untested explanation is that chronic exposure to BPA might eventually compromise metabolizing capacity of the liver, as suggested previously ([@r15]), leading to progressively elevated concentrations of active BPA. Variation in animal feeding habits might also account for differences between diet compared with bolus exposure, although there is no reason to presume that mice would exhibit different feeding patterns after 7 days versus 1 day of BPA-*d*~6~ exposure, particularly as the samples were collected at the same time of day (1900 hours). Another consideration is that the stage of the estrous cycle might influence BPA metabolism and accumulation. However, in a previous study [@r22] suggested that menstrual cycle stage did not influence urinary BPA concentrations in samples from 60 women taken 2 and 4 weeks apart. In short, the reason why circulating unconjugated BPA-*d*~6~ increased over time after diet exposure eludes us, but studies are currently under way with radioactive BPA to determine where the ingested BPA becomes concentrated.

Conclusions
===========

Our data highlight possible limitations of single oral bolus administration of BPA, the experimental design used for the majority of studies examining the pharmacokinetics of BPA exposure in both animal models and humans ([@r7], [@r8]; [@r28]; [@r34]). Results of the present study suggest that the presence of food may increase internal exposure to bioactive BPA, possibly by an inhibitory effect on first-pass (presystemic) elimination, and thus diet exposure is presumably the more relevant way of modeling the natural route of contact to BPA that occurs in humans. In contrast, experiments using single oral bolus exposure may not only underestimate exposure to bioactive BPA in serum but also lead to inaccurate conclusions concerning long-term concentrations of active BPA in serum or plasma of animals and humans. Our data may explain how although humans can rapidly eliminate BPA when it is provided as a single bolus ([@r35]), continuous external BPA exposure appears to lead to sustained concentrations that are detectable in serum or plasma of humans who have not been knowingly exposed to this endocrine-disrupting chemical (FDA 2008; [@r33]; [@r36]). We conclude that exposure through the diet provides a better approach for assessing the impact of BPA on internal organ systems than delivery as a single bolus.

Supplemental Material
=====================

###### 

Click here for additional data file.
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